Skip to main content
HIKMA Pharmaceuticals PLC logo

HIKMA Pharmaceuticals PLC — Investor Relations & Filings

Ticker · HIK ISIN · GB00B0LCW083 LEI · 549300BNS685UXH4JI75 IL Manufacturing
Open in API
Filings indexed 827 across all filing types
Latest filing 2023-04-28 AGM Information
Country GB United Kingdom
Listing IL HIK

About HIKMA Pharmaceuticals PLC

https://www.hikma.com/home/

Hikma Pharmaceuticals is a global pharmaceutical company that develops, manufactures, and markets a broad portfolio of pharmaceutical products. The company's offerings include a wide range of generic, branded, specialty, and in-licensed medicines. It is a significant supplier of generic injectable products to hospitals and also provides oral generics and other specialty medications. With a focus on producing high-quality medicines, Hikma aims to make its products accessible to patients and healthcare providers across its key markets in North America, Europe, and the Middle East & North Africa (MENA) region.

Recent filings

Filing Released Lang Actions
Special Resolutions passed at AGM
AGM Information Classification · 99% confidence The document explicitly states it contains the 'RESOLUTIONS PASSED AT THE ANNUAL GENERAL MEETING ON 28 APRIL 2023'. It details specific resolutions (18, 21, 22, 23, 24) concerning share allotment, pre-emption rights, and share purchases, which are typical items voted upon and documented following an AGM. This content directly aligns with the purpose of documenting the outcomes of an Annual General Meeting.
2023-04-28 English
Trading Statement
Earnings Release Classification · 99% confidence The document is explicitly titled as an 'update on current trading ahead of its Annual General Meeting' and is distributed via RNS (London Stock Exchange news service). It provides detailed operational updates for Q1/Year-to-Date across its Injectables, Branded, and Generics segments, including updated full-year guidance for Generics revenue. It also mentions the final dividend is 'Subject to approval at today's Annual General Meeting'. Because it is a trading update released shortly before the AGM, it functions as an Earnings Release (ER) or a comprehensive trading update, but the context of being 'ahead of its Annual General Meeting' and providing detailed performance metrics strongly suggests it is an Earnings Release (ER) or a comprehensive Interim Report (IR) if it were mid-year. Since it is a trading update covering the start of the year and updating guidance, it fits best as an Earnings Release (ER) which often precedes the formal AGM/10-K filing. However, the document is distributed via RNS and contains information that is often part of a broader regulatory filing or an announcement of results. Given the content is a detailed trading update with guidance revision, it is most accurately classified as an Earnings Release (ER). The mention of the AGM is contextual, not the primary focus (which is the trading performance). The document length (8265 chars) is substantial enough to be more than just a simple announcement of a report (RPA/RNS). FY 2022
2023-04-28 English
Director/PDMR Shareholding
Director's Dealing Classification · 100% confidence The document text contains an RNS Number (2716X) and is dated April 24, 2023. The content explicitly details 'Notification and public disclosure of transactions by persons discharging managerial responsibilities' (PDMRs) regarding the vesting of conditional share awards under an Executive Incentive Plan (EIP). This type of mandatory disclosure concerning personal share transactions by directors and executives is specifically classified as Director's Dealing.
2023-04-24 English
Directorate Change
Board/Management Information Classification · 100% confidence The document is a formal announcement released via RNS (Regulatory News Service) on April 12, 2023, detailing the appointment of Riad Mishlawi as the new Chief Executive Officer (CEO) of Hikma Pharmaceuticals PLC, effective September 1, 2023. This concerns a change in senior management/board composition. This directly matches the definition for Board/Management Information (MANG). Although it is an RNS release, the core content is a specific management announcement, making MANG the most precise classification over the general RNS fallback.
2023-04-12 English
Block listing Interim Review
Remuneration Information Classification · 99% confidence The document is explicitly titled 'RNS Number : 1243V' and contains multiple sections labeled 'Block Listing Six Monthly Return' dated 03 April 2023, covering the period from 1 October 2022 to 31 March 2023. It details the status of various stock option and incentive plans (SOP, LTIP, MIP, EIP) regarding unallotted securities. The presence of 'RNS Number' and the closing statement referencing 'RNS, the news service of the London Stock Exchange' strongly indicates this is a regulatory announcement disseminated via the RNS system. Since it is a specific regulatory filing that doesn't fit the definitions for 10-K, ER, IR, or DIRS, the most appropriate general category for a standard regulatory announcement disseminated via RNS is 'Regulatory Filings' (RNS), although it is a very specific type of filing related to share schemes.
2023-04-03 English
Total Voting Rights
Share Issue/Capital Change Classification · 99% confidence The document is a notification filed via RNS (Regulatory News Service) on April 3, 2023, titled 'Total Voting Rights and Capital'. It explicitly states the total number of issued shares and the number of treasury shares as of March 31, 2023, referencing the FCA's Disclosure Guidance and Transparency Rules. This type of announcement, which communicates the denominator for shareholder notification obligations regarding ownership changes, is a specific regulatory disclosure. While it relates to capital structure, it is not a financing activity (CAP) or a general share issue (SHA). It is a mandatory regulatory update concerning voting rights, which fits best under the general 'Regulatory Filings' (RNS) category, as it is a standard, short regulatory update that doesn't fit the more specific categories like DVA (which is for *results* of votes) or DIV (dividends). Given the context of RNS distribution and the nature of the content (Total Voting Rights), RNS is the most appropriate general regulatory classification.
2023-04-03 English

Browse filings by year

22 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.